XML 27 R16.htm IDEA: XBRL DOCUMENT v3.25.1
Stock Incentive Plans
 3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Stock Incentive Plans STOCK INCENTIVE PLANS
Stock Options, Restricted Stock Units (“RSU”), and Performance Restricted Stock Units (“PSU”)
The following table summarizes option, RSU, and PSU activity under the Company’s 2014 Equity Incentive Plan, 2016 Inducement Equity Incentive Plan and 2019 Inducement Equity Incentive Plan, 2024 Equity Incentive Plan, and related information:
Shares
Available
for Grant		Stock
Options
Outstanding		Weighted-
Average
Exercise
Price

RSU/PSU Outstanding
Weighted-
Average
Grant Date
Fair Value
Balance—December 31, 20244,559,101 3,409,912 $22.63 4,842,670 $15.38 
Shares expired
(1,398,171)— — — — 
Common stock awards for services(856)— — — — 
RSUs granted(1,013,286)— — 1,013,286 19.62 
RSUs vested— — — (367,450)16.24 
PSUs granted
(473,754)— — 236,877 19.61 
PSUs vested
— — — (256,711)15.74 
Options exercised— (141,050)21.61 — — 
RSUs forfeited10,500 — — (376,425)13.28 
PSUs forfeited
— — — (34,937)18.50 
Options forfeited— (72,359)23.83 — — 
Options expired— (252,065)41.48 — — 
Balance—March 31, 20251,683,534 2,944,438 $21.03 5,057,310 $16.47 
The total intrinsic value of options exercised was $0.4 million and $0.1 million for the three months ended March 31, 2025 and 2024.
As of March 31, 2025, the total intrinsic value of outstanding RSUs was approximately $92.7 million and there were $44.2 million of unrecognized compensation costs related to RSUs, which are expected to be recognized over a weighted-average period of 2.20 years.
The PSUs granted to employees consist of financial and operational metrics to be met over a performance period of two years. The number of shares outstanding was 572,460 and 412,843 as of March 31, 2025 and 2024, respectively. The weighted-average remaining recognition period was 2.31 years and 0.84 years for the three months ended March 31, 2025 and 2024, respectively.
Options outstanding that have vested and are expected to vest at March 31, 2025 are as follows:
Number of Options Issued
(In thousands)
Weighted-Average
Exercise Price		Weighted-Average Remaining Contractual Life (Years)Aggregate Intrinsic Value
(In thousands)
Vested1,777 $24.83 5.60$4,226 
Expected to vest1,068 15.11 8.766,337 
Total2,845 $10,563 

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock at March 31, 2025 for stock options that were in-the-money.
The total fair value of options that vested during the three months ended March 31, 2025 was $1.2 million. As of March 31, 2025, there were approximately $9.5 million of unrecognized compensation costs related to stock options, which are expected to be recognized over a weighted-average period of 2.67 years.
2014 Employee Stock Purchase Plan
The Company has an Employee Stock Purchase Plan (the “ESPP”) under which employees can purchase shares of its common stock based on a percentage of their compensation, but not greater than 15% of their respective earnings, provided an eligible employee’s right to purchase shares of the Company’s common stock may not accrue at a rate which exceeds $25,000 of the fair market value of such shares for each calendar year in which such rights are outstanding. The ESPP has consecutive offering periods of approximately six months in length. The purchase price per share must be equal to the lower of 85% of the fair value of the common stock on the first day of the offering period or on the exercise date.
During the offering period in 2024 that ended on December 31, 2024, 66,747 shares were purchased pursuant to the ESPP for aggregate proceeds of $0.9 million from the issuance of such shares, which occurred on January 2, 2025. 
Valuation Assumptions
The estimated fair values of employee stock options and ESPP shares were estimated using the Black-Scholes option pricing model based on the following weighted average assumptions:
Three Months Ended March 31,
20252024
Employee stock options
Expected term (in years)N/AN/A
Expected volatilityN/AN/A
Risk-free interest rateN/AN/A
Expected dividend yieldN/AN/A
Employee stock purchase plan
Expected term (in years)0.50.5
Expected volatility69.60%75.91%
Risk-free interest rate4.23%5.38%
Expected dividend yield—%—%
Risk-free Interest Rate: The Company based the risk-free interest rate over the expected term of the award based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of grant.
Volatility: The Company used an average historical stock price volatility of its own stock.
Expected Term: The expected term represents the period for which the Company’s stock-based compensation awards are expected to be outstanding and is based on analyzing the vesting and contractual terms of the awards and the holders’ historical exercise patterns and termination behavior.
Expected Dividends: The Company has not paid and does not anticipate paying any dividends in the near future.
There were no stock options granted during the periods.
Stock-Based Compensation Expense
The following table summarizes stock-based compensation expense relating to employee and non-employee stock-based awards for the three months ended March 31, 2025 and 2024, included in the condensed consolidated statements of operations as follows (in thousands):
Three Months Ended March 31,
20252024
Cost of testing services$363 $457 
Cost of product231 317 
Cost of patient and digital solutions220 372 
Research and development1,359 1,760 
Sales and marketing2,584 3,044 
General and administrative4,174 10,623 
Total$8,931 $16,573